This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress

This study has been completed.
Information provided by:
Lantheus Medical Imaging Identifier:
First received: June 27, 2008
Last updated: August 17, 2011
Last verified: August 2011
The purpose of this clinical research study is to learn the biodistribution of injection of BMS747158 at stress and assess the safety of two doses of BMS747158

Condition Intervention Phase
Healthy Volunteers Drug: BMS747158 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase I Dosimetry, Biodistribution and Safety Study of BMS747158 in Healthy Subjects Undergoing 2-Day Rest/Stress Positron Emission Tomography

Further study details as provided by Lantheus Medical Imaging:

Primary Outcome Measures:
  • Dosimetry analysis following whole body imaging after stress injection [ Time Frame: Imaging takes place approximately 0 - 300 minutes post injection ]

Secondary Outcome Measures:
  • Safety analysis following vital signs, ECGs, EEG, neuro and physical exams, telephone and visit follow up, and blood draws for chemistry and hematology post injection of BMS747158 at rest and stress [ Time Frame: Screening (14 days prior to dosing) through 14 days post dose administration ]

Enrollment: 12
Study Start Date: June 2008
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: BMS747158
2 IV injection of ~11 mCi (total) F-18 labeled compound


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 18-40
  • BMI 18-30 kg/m2
  • No active or chronic illnesses
  • If female: not pregnant, use of birth control or not of child-bearing potential

Exclusion Criteria:

  • Significant active or chronic illness
  • Any neurological disorder
  • GI disease within 3 months
  • Recent infection
  • Major surgery within 4 weeks
  • Donation of blood within 4 weeks
  • Blood transfusion within 4 weeks
  • Recent history drug/alcohol abuse
  • Head trauma
  • Significant screening ECG, EEG, lab tests, physical exam and vital signs abnormalities
  • Prescription or OTC drugs within 2 weeks
  • Exposure to any other investigational
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00707538

United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
United States, Maryland
John Hopkins University
Baltimore, Maryland, United States, 21287
Sponsors and Collaborators
Lantheus Medical Imaging
Principal Investigator: Jamshid Maddahi, MD University of California, Los Angeles
  More Information

Responsible Party: Dana Washburn, MD, Lantheus Medical Imaging Identifier: NCT00707538     History of Changes
Other Study ID Numbers: BMS747158-102
Study First Received: June 27, 2008
Last Updated: August 17, 2011 processed this record on September 21, 2017